ReviewCancers2018
Role of COX-2/PGE2 Mediated Inflammation in Oral Squamous Cell Carcinoma.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Inflammation-driven carcinogenesis in oral cancer: A systematic review of cellular mechanisms and clinical perspectives.The Indian journal of medical research · 2026Pooled it
- Review
- Mechanobiological and Molecular Alterations in the Aging Dentin-Pulp Complex.Life (Basel, Switzerland) · 2026Article
- Article
- Cyclooxygenase-2 expression in advanced oral squamous cell carcinoma: a biomarker of poor prognosis.BMC oral health · 2025Article
- Expression of FoxP3 in oral squamous cell carcinoma and its biological significance.Discover oncology · 2025Article
- Effects on Oral Squamous Carcinoma Cell Lines and Their Mechanisms of Pyrazole N-Aryl Sulfonate: A Novel Class of Selective Cyclooxygenase-2 Inhibitors.International journal of molecular sciences · 2025Article
- Article
- Bovine serum albumin nanoparticles encapsulating Dasatinib and Celecoxib for oral cancer: Preparation, characterization, and in-vitro evaluation.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- High expression of prostaglandin EP4 receptor mRNA in feline head and neck squamous cell carcinoma.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2025Article
- Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors.Molecular cancer therapeutics · 2025Article
- Beyond Genetics: Exploring Lifestyle, Microbiome, and Social Determinants in Oral Cancer Development.Cancers · 2025Review
- Chemoprotective effect of nimbolide against N-methyl-N-nitrosourea induced gastric cancer via alteration of apoptosis and NF-κB signaling pathway.Acta cirurgica brasileira · 2025Article
- Effects of perioperative anesthetics on the postoperative prognosis of patients undergoing surgery for cervical cancer.Frontiers in pharmacology · 2025Review
- Curcumin in oral health: mechanisms, clinical evidence, and delivery strategies.Frontiers in pharmacology · 2025Review
- Cancer Stem Cell Marker CD147 Expression in Erosive Oral Lichen Planus Compared to Moderately and Severely Dysplastic Leukoplakia.Reports (MDPI) · 2024Article
- Anti-Inflammatory Effects of ParaprobioticJournal of microbiology and biotechnology · 2024Article
- Integrated mRNA and miRNA analysis reveals the regulatory network of oxidative stress and inflammation in Coilia nasus brains during air exposure and salinity mitigation.BMC genomics · 2024Article
- Rel Family Transcription Factor NFAT5 Upregulates COX2 via HIF-1α Activity in Ishikawa and HEC1a Cells.International journal of molecular sciences · 2024Article
- The role of bidirectional communication between the adipokines and the endogenous opioid system in an experimental mouse model of colitis-associated colorectal cancer.Pharmacological reports : PR · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A significant amount of research indicates that the cyclooxygenase/prostaglandin E2 (PGE2) pathway of inflammation contributes to the development and progression of a variety of cancers, including squamous cell carcinoma, or the oral cavity and oropharynx (OSCC). Although there have been promising results from studies examining the utility of anti-inflammatory drugs in the treatment of OSCC, this strategy has been met with only variable success and these drugs are also associated with toxicities that make them inappropriate for some OSCC patients. Improved inflammation-targeting therapies require continued study of the mechanisms linking inflammation and progression of OSCC. In this review, a synopsis of OSCC biology will be provided, and recent insights into inflammation related mechanisms of OSCC pathobiology will be discussed. The roles of prostaglandin E2 and cluster of differentiation factor 147 (CD147) will be presented, and evidence for their interactions in OSCC will be explored. Through continued investigation into the protumourigenic pathways of OSCC, more treatment modalities targeting inflammation-related pathways can be designed with the hope of slowing tumour progression and improving patient prognosis in patients with this aggressive form of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.